Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Therapeutic Choices for Psoriasis and Mental Health

J Dermatolog Treat; ePub 2018 May 14; Salame, et al

Therapeutic choices for psoriasis impact mental health outcomes, according to a recent study, which determined that biologic therapy is associated with reductions in psychological distress and depression as compared to oral therapy in the US adult moderate-to-severe psoriasis population. Researchers performed a nationwide, cross-sectional study comparing 2,303,534 (weighted) adults with moderate-to-severe psoriasis on biologic vs oral therapies and their associated mental health outcomes using the 2003-2015 Medical Expenditure Panel Survey (MEPS). Mental health outcomes were measured with the Kessler 6 (K6), a validated measure of psychological distress, and Patient Health Questionnaire 2 (PHQ2), a screening tool for depression. They found:

  • The mean K6 score for residents on biologic therapies was significantly lower than that of residents on oral therapies (2.72 vs 3.70).
  • The mean PHQ2 score for residents on biologic therapies was also significantly lower than that of residents on oral therapies (0.540 vs 0.890).
  • Based on adjusted multivariable linear regression models, biologic therapy was associated with significant reductions in K6 and PHQ2 scores compared to oral therapy.
Citation:

Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: A population-based study. [Published online ahead of print May 14, 2018]. J Dermatolog Treat. doi:10.1080/09546634.2018.1476654

This Week's Must Reads

Link Between AD and Autoimmune Disorders, J Am Acad Dermatol; ePub 2018 Oct 1; Narla, et al

Predictors of Mucosal Melanoma Survival, J Am Acad Dermatol; ePub 2018 Oct 5; Altieri, et al

Prevalence of Acne Vulgaris Among Patients with HS, J Am Acad Dermatol; ePub 2018 Oct 1; Wertenteil, et al

Skin Disease Epidemiology in a Diverse Population, J Drugs Dermatol; 2018 Oct; Gaulding, et al

Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8

Must Reads in Psoriasis

Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8

Latent TB Prevalent in Patients with Psoriasis, J Dermatolog Treat; 2018 Nov; Lee, Amin, et al

Understanding Scope of Cutaneous Pain in Psoriasis, J Dermatolog Treat; ePub 2018 Sep 26; Pithadia, et al

Ixekizumab Proves Effective in Psoriasis Treatment, J Clin Pharmacol; 2018 Nov; Chigutsa, et al

QOL Impaired in Young Adults with Psoriasis, J Dermatolog Treat; ePub 2018 Sep 7; Bronckers, et al